- Investigator
- Eric I Jeng
Clinical trials
-
LVAD Biopsy -
BT015: Blood-Brain Barrier Disruption (BBBD) Liquid Biopsy in Subjects With GlioBlastoma Brain Tumor The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
- Investigator
- Justin D Hilliard
- Ages
- 18 Years - 80 Years
- Sexes
- All
-
BIO89-100-132 The ENLIGHTEN-Cirrhosis Study The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
- Investigator
- Ginger Clark
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
- Investigator
- Ginger Clark
- Ages
- 18 Years - 70 Years
- Sexes
- All
-
NIH AIM 2 - Low Dose Pioglitazone in NASH To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- Ages
- 21 Years - 75 Years
- Sexes
- All